Overview

Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC). There are 2 treatments in this study. Both treatments are injected under the skin. Allergovit® Grasses works by helping the body's immune system get used to grass-pollen before the grass pollen season begins which may lead to decreased sensitivity and reduced allergy symptoms during the grass season. Placebo treatment does not contain grass pollen mixture, and is not expected to reduce allergic symptoms overtime.
Phase:
Phase 2
Details
Lead Sponsor:
Allergopharma GmbH & Co. KG
Collaborator:
Inflamax Research Incorporated